Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels, which stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner. It is unique among DPP-4 inhibitors in that it is primarily excreted via the biliary/fecal route rather than the renal route.
## Primary Indications
Type 2 diabetes mellitus (as an adjunct to diet and exercise to improve glycemic control).
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
Safety and effectiveness in pediatric patients (under 18 years) have not been established. Use is generally not recommended.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required (regardless of eGFR).
* **Hepatic Impairment:** No dose adjustment required.
## Contraindications
* History of a serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
## Adverse Effects
* **Common:** Nasopharyngitis.
* **Serious:** Acute pancreatitis (discontinue if symptoms occur), severe and disabling arthralgia, bullous pemphigoid, and hypersensitivity reactions.
* **Hypoglycemia:** Risk is low when used as monotherapy or with metformin; risk increases when used in combination with insulin or sulfonylureas.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin efficacy; consider alternative therapy if glycemic control is inadequate.
* **Insulin/Sulfonylureas:** May increase the risk of hypoglycemia. Consider dose reductions of the insulin or secretagogue when adding linagliptin.
## Monitoring
* **HbA1c:** Assess at baseline and every 3–6 months.
* **Blood Glucose:** Self-monitoring as instructed by the clinician.
* **Pancreatitis:** Monitor for persistent, severe abdominal pain.
## Clinical Pearls
* **Renal Advantage:** Because it is primarily excreted non-renally, it is an excellent choice for patients with significant renal impairment or end-stage renal disease (ESRD).
* **Administration:** May be taken with or without food.
* **Weight:** Considered weight-neutral.
***
*Disclaimer: This information is for educational purposes and does not substitute for professional medical judgment. Always consult the latest FDA-approved prescribing information or institutional clinical guidelines before prescribing or administering medication.*
